The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Cited by
Sorted by citations
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationGuidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.2 · Cited by 1,273
Self-citationRecent Developments in Mendelian Randomization Studies
Zheng, J., Baird, D. A., Borges, M. C., Bowden, J., Hemani, G., Haycock, P., Evans, D. M., & Smith, G. D. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0128-6 · Cited by 1,147
Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Self-citationMendelian Randomization: Concepts and Scope
Richmond, R. C., & Davey Smith, G. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040501 · Cited by 841
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
Mendelian randomization for cardiovascular diseases: Principles and applications
Larsson, S. C., Butterworth, A. S., & Burgess, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad736 · Cited by 735
Guidelines for performing Mendelian randomization investigations: update for summer 2023
Burgess, S., Smith, G. D., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Kutalik, Z., Holmes, M. V., Minelli, C., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.3 · Cited by 747
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Self-citationBurgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689
Self-citationMendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Vekić, J., Zeljković, A., Stefanović, A., Jelić‐Ivanović, Z., & Spasojević‐Kalimanovska, V. (2018) · Metabolism · doi:10.1016/j.metabol.2018.11.005 · Cited by 623
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
Self-citationGenetic drug target validation using Mendelian randomisation
Schmidt, A. F., Finan, C., Gordillo‐Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16969-0 · Cited by 575
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511
Self-citationTime Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
Domanski, M. J., Tian, X., Wu, C. O., Reis, J. P., Dey, A. K., Gu, Y., Zhao, L., Bae, S., Liu, K., Hasan, A. A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.059 · Cited by 411
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Self-citationPCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D., Oliver‐Williams, C., Wood, A., Butterworth, A. S., Angelantonio, E. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 345
Self-citationUsing Mendelian Randomization to Improve the Design of Randomized Trials
Ference, B. A., Holmes, M. V., & Smith, G. D. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040980 · Cited by 338
Self-citationImmune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benvéniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 342
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J., & Bustamante, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0350-6 · Cited by 338
on behalf of the China Kadoorie Biobank Collaborative Group, Sun, L., Clarke, R., Bennett, D., Yu, C., Walters, R. G., Hill, M., Parish, S., Millwood, I. Y., Bian, Z., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0366-x · Cited by 318
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30158-5 · Cited by 315
Wang, Y., Jing, J., Meng, X., Pan, Y., Wang, Y., Zhao, X., Lin, J., Li, W., Jiang, Y., Li, Z., et al. (2019) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000242 · Cited by 313
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2017) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 303
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Self-citationTreating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Self-citationLyons, P., Peters, J. E., Alberici, F., Liley, J., Coulson, R., Astle, W. J., Baldini, C., Bonatti, F., Cid, M. C., Elding, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12515-9 · Cited by 287
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Self-citationPaternoster, L., Tilling, K., & Davey Smith, G. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006944 · Cited by 271
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M. J., Köenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Lawrence, D., Friedman, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac594 · Cited by 239
Ference, B. A., Bhatt, D. L., Catapano, A. L., Packard, C. J., Graham, I. M., Kaptoge, S. K., Ference, T. B., Guo, Q., Laufs, U., Ruff, C. T., et al. (2019) · JAMA · doi:10.1001/jama.2019.14120 · Cited by 228
Self-citationWalker, V. M., Smith, G. D., Davies, N. M., & Martin, R. M. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx207 · Cited by 216
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy357 · Cited by 209
Self-citationMetabolomics and Proteomics in Type 2 Diabetes
Chen, Z., & Gerszten, R. E. (2020) · Circulation Research · doi:10.1161/circresaha.120.315898 · Cited by 214
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 203
Cerebral small vessel disease genomics and its implications across the lifespan
Sargurupremraj, M., Suzuki, H., Jian, X., Sarnowski, C., Evans, T. E., Bis, J. C., Eiriksdottir, G., Sakaue, S., Terzikhan, N., Habes, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19111-2 · Cited by 214
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx549 · Cited by 200
Self-citationCausal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?
Yarmolinsky, J., Wade, K. H., Richmond, R. C., Langdon, R., Bull, C. J., Tilling, K. M., Relton, C. L., Lewis, S. J., Smith, G. D., & Martin, R. M. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-1177 · Cited by 188
Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes
Hindy, G., Engström, G., Larsson, S. C., Traylor, M., Markus, H. S., Melander, O., & Orho‐Melander, M. (2018) · Stroke · doi:10.1161/strokeaha.117.019653 · Cited by 192
Borges, M. C., Haycock, P., Zheng, J., Hemani, G., Holmes, M. V., Smith, G. D., Hingorani, A. D., & Lawlor, D. A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02399-w · Cited by 180
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Self-citationThe LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., Braunwald, E., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 196
Self-citationMendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 181
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 180
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Girolamo, F. G. D., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 188
Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3502 · Cited by 172
Ference, B. A., Cannon, C. P., Landmesser, U., Lüscher, T. F., Catapano, A. L., & Ray, K. K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx450 · Cited by 161
Self-citationStatistical methods for cis‐Mendelian randomization with two‐sample summary‐level data
Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22506 · Cited by 159
Hypertension with diabetes mellitus complications
Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-017-0008-y · Cited by 166
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Farmer, R. E., Mathur, R., Schmidt, A. F., Bhaskaran, K., Fatemifar, G., Eastwood, S. V., Finan, C., Denaxas, S., Smeeth, L., & Chaturvedi, N. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011638 · Cited by 144
Fonarow, G. C., KEECH, A. C., Pedersen, T. R., Giugliano, R. P., Sever, P. S., Lindgren, P., van Hout, B., Villa, G., Qian, Y., Somaratne, R. M., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2762 · Cited by 153
Self-citationAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Genomic insights into the causes of type 2 diabetes
Langenberg, C., & Lotta, L. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31132-2 · Cited by 154
Genetic Determinants of Lipids and Cardiovascular Disease Outcomes
Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason, A. M., Bell, S., Gill, D., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002711 · Cited by 141
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Schmidt, A. F., Hunt, N. B., Gordillo‐Marañón, M., Charoen, P., Drenos, F., Casas, J. P., Mika Kivimaki, B., Lawlor, D. A., Giambartolomei, C., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25703-3 · Cited by 142
Leiter, L. A., Cariou, B., Müller‐Wieland, D., Colhoun, H. M., Prato, S. D., Tinahones, F. J., Ray, K. K., Bujas‐Bobanovic, M., Domenger, C., Mandel, J., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13114 · Cited by 138
Averna, M. R., Banach, M., Bruckert, É., Drexel, H., Farnier, M., Gaiță, D. I., Magni, P., März, W., Masana, L., Silva, A. M. E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 143
Self-citationHemani, G., Zheng, J., Wade, K. H., Laurin, C., Elsworth, B., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/078972 · Cited by 135
Cholesterol metabolism, pancreatic β-cell function and diabetes
Perego, C., Dalt, L. D., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.012 · Cited by 141
Self-citationMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 286
Yuan, Z., Zhu, H., Zeng, P., Yang, S., Sun, S., Yang, C., Liu, J., & Zhou, X. (2020) · Nature Communications · doi:10.1038/s41467-020-17668-6 · Cited by 129
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Benn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 133
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCoptisine fromCoptis chinensisexerts diverse beneficial properties: A concise review
Wu, J., Luo, Y., Deng, D., Su, S., Li, S., Li, X., Hu, Y., Wang, P., & Meng, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14725 · Cited by 125
Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 128
Paige, E., Masconi, K. L., Tsimikas, S., Kronenberg, F., Santer, P., Weger, S., Willeit, J., Kiechl, S. J., & Willeit, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0520-z · Cited by 121
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
Bohula, E. A., Marston, N., Bhatia, A. K., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Park, J., Kuder, J., Murphy, S. A., Walsh, E., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514428 · Cited by 141
Self-citationMendelian Randomization Analysis as a Tool to Gain Insights into Causes of Diseases: A Primer
Tin, A., & Köttgen, A. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020121760 · Cited by 118
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction
Dalt, L. D., Castiglioni, L., Baragetti, A., Audano, M., Svecla, M., Bonacina, F., Pedretti, S., Uboldi, P., Benzoni, P., Giannetti, F., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab431 · Cited by 123
Self-citationChildhood adiposity and risk of type 1 diabetes: A Mendelian randomization study
Censin, J. C., Nowak, C., Cooper, N., Bergsten, P., Todd, J. A., & Fall, T. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002362 · Cited by 119
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034942 · Cited by 109
Packard, C. J., Chapman, M. J., Sibartie, M., Laufs, U., & Masana, L. (2021) · Heart · doi:10.1136/heartjnl-2020-318760 · Cited by 114
Self-citationMendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
Rodriguez‐Broadbent, H., Law, P., Sud, A., Palin, K., Tuupanen, S., Gylfe, A. E., Hänninen, U. A., Cajuso, T., Tanskanen, T. J., Kondelin, J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30709 · Cited by 103
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 116
Perkins, B. A., Caskey, C. T., Brar, P., Dec, E., Karow, D. S., Kahn, A. M., Hou, Y. C., Shah, N., Boeldt, D., Coughlin, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706096114 · Cited by 104
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 108
Statins are associated with increased insulin resistance and secretion
Abbasi, F., Lamendola, C., Harris, C. S., Harris, V., Tsai, M.-S., Tripathi, P., Abbas, F., Reaven, G. M., Reaven, P. D., Snyder, M. P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316159 · Cited by 98
Ray, K. K., Leiter, L. A., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Henry, R. R., Tinahones, F. J., Bujas‐Bobanovic, M., Domenger, C., Letierce, A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13257 · Cited by 104
Burgess, S. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.26250 · Cited by 118
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J., Sharp, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.070 · Cited by 101
Factorial Mendelian randomization: using genetic variants to assess interactions
Rees, J. M. B., Foley, C. N., & Burgess, S. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz161 · Cited by 101
Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes
Georgakis, M. K., Gill, D., Webb, A. J. S., Εvangelou, Ε., Elliott, P., Sudlow, C. L. M., Dehghan, A., Malik, R., Tzoulaki, I., & Dichgans, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009814 · Cited by 99
Can LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mı́nguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 102
How to use Mendelian randomization to anticipate the results of randomized trials
Ference, B. A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx462 · Cited by 96
Self-citationRay, K. K., Nicholls, S. J., Li, N., Louie, M. J., Brennan, D., Lincoff, A. M., & Nissen, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00316-9 · Cited by 99
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Self-citationA Comprehensive Review of PCSK9 Inhibitors
Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221100107 · Cited by 103
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
